Welcome to our dedicated page for Exagen news (Ticker: XGN), a resource for investors and traders seeking the latest updates and insights on Exagen stock.
Exagen Inc. (Nasdaq: XGN) is a leader in autoimmune diagnostics, providing specialized testing solutions through its CLIA-certified laboratory and proprietary AVISE® platform. This page serves as the definitive source for verified news and announcements related to the company’s advancements in rheumatology diagnostics, financial developments, and strategic initiatives.
Investors and healthcare professionals will find timely updates on regulatory milestones, clinical study outcomes, and operational achievements. Our curated collection includes earnings reports, partnership announcements, and insights into biomarker research that drives Exagen’s industry-leading tests for conditions like lupus and rheumatoid arthritis.
All content undergoes rigorous verification to ensure alignment with financial disclosure standards and medical accuracy. Bookmark this page to efficiently track Exagen’s progress in improving diagnostic clarity for autoimmune diseases while staying informed about its role in advancing personalized medicine.
Exagen (NASDAQ: XGN), a leader in autoimmune testing, has scheduled its Q2 2025 financial results announcement for July 29, 2025, before market opening. The company will host a conference call at 8:30 AM ET featuring CEO John Aballi and CFO Jeff Black.
Investors can join via phone (201-389-0918 U.S. or +1-877-407-0890 international) or through the webcast link on Exagen's investor relations website. A replay will be available until August 12, 2025, accessible by phone using passcode 13753132 or through the company website.
Exagen Inc. (XGN) has successfully completed its public offering, raising approximately $20.2 million in gross proceeds. The offering included the sale of 3,350,000 shares of common stock, plus an additional 502,500 shares due to the full exercise of the underwriter's option, all priced at $5.25 per share. The transaction closed on May 9, 2025, with Canaccord Genuity acting as the sole bookrunner. The offering was conducted under Exagen's shelf registration statement previously filed with the SEC.
Exagen Inc. (XGN) has announced the pricing of its public offering of 3,350,000 shares of common stock at $5.25 per share. The offering is expected to generate gross proceeds of $17.6 million before deducting underwriting discounts and expenses. The company has granted underwriters a 30-day option to purchase up to an additional 502,500 shares under the same terms.
The offering, scheduled to close on May 9, 2025, is being conducted through Canaccord Genuity as the sole bookrunner. The public offering is made pursuant to a shelf registration statement on Form S-3 that was declared effective by the SEC on November 29, 2023.
Exagen Inc. (XGN) has secured a senior secured credit facility of up to $75 million with Perceptive Advisors The company received an initial $25 million tranche at closing to refinance existing debt with Innovatus Capital Partners and strengthen its balance sheet.
The facility includes additional tranches:
- $10 million available through March 2026 (revenue milestone-based)
- $10 million through December 2026 (revenue milestone-based)
- $30 million through March 2027 for business development initiatives
The loan terms include Term SOFR + 7% interest (SOFR floor 4.75%), 60-month interest-only payments, and warrants for 400,000 shares initially, with potential for 750,000 additional warrants tied to future tranches. The loan is secured by substantially all of Exagen's assets.
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, has scheduled its first quarter 2025 financial results announcement for May 5, 2025, before market opening. The company will host a conference call at 8:30 a.m. ET (5:30 a.m. PT) featuring President and CEO John Aballi and CFO Jeff Black.
Participants can join via phone at 201-389-0918 (U.S.) or +1-877-407-0890 (international), or through webcast available on the company's investor relations website. A replay will be accessible until May 19, 2025, through phone (201-612-7415 U.S., +1-877-660-6853 international, passcode 13753132) or webcast.
Exagen Inc. (XGN) reported strong financial results for Q4 and full-year 2024, achieving record total revenue of $55.6 million. The company demonstrated significant improvements in key metrics, including a 300 basis point increase in gross margin to 62.1% in Q4 and 59.5% for the full year.
The AVISE® CTD test reached a milestone of 1,000,000 patients tested, with its trailing twelve-month average selling price expanding to $411, a $75 increase per test. The company reduced its net loss by $1.8 million in Q4 and over $8 million for the full year compared to 2023.
Looking ahead, Exagen expects Q1 2025 revenue of at least $14.5 million and anticipates achieving positive adjusted EBITDA by Q4 2025. The company ended 2024 with $22.2 million in cash and restricted cash.
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, has scheduled the release of its fourth quarter and full-year 2024 financial results for March 11, 2025, before market opening. The company will host a conference call at 8:30 AM ET (5:30 AM PT) with President and CEO John Aballi and CFO Jeff Black to discuss the results.
Participants can join via phone at 201-389-0918 (U.S.) or +1-877-407-0890 (international), or through webcast available on the company's investor relations website. A replay will be accessible until April 14, 2025, at 11:59 PM ET through phone (201-612-7415 U.S., +1-877-660-6853 international, passcode 13751928) or webcast.